>>> US Gapping down

Gapping down
In reaction to disappointing earnings/guidance:

  • GSM -37.1%, FRAN -11.7%, HIBB -9.6%, BKE -8.7%, MTL -3.2%

M&A news:

  • SWX -1.4% (to acquire Linetec Services through subsidiary Centuri Construction Group for overall initial transaction cost of approx. $336 mln; commences underwritten public offering of 3.1 mln shares of common stock)

Other news:

  • HALO -12.3% (FDA has agreed to its request to change the primary endpoint of the HALO-301 study to "overall survival")
  • GTHX -11.1% (reports updated myelopreservation data from Phase 2 trial of trilaciclib in combination with chemotherapy/Tecentriq in first-line small cell lung cancer), ACAD -6.5% (proposes public offering of $200 mln of its common stock)
  • AMRN -5.4% (prices underwritten public offering of its American Depositary Shares for gross proceeds of approximately $200 mln)
  • IMGN -4.9% (announces resignation of CFO David Johnston, effective immediately)
  • KOS -3.5% (pricing of secondary offering of 15 mln of its common shares at $5.43 per share)
  • DXCM -2.4% (to offer $750 mln of Convertible Senior Notes due 2023 in a private placement )
  • GOOS -2.4% (announces secondary offering of 10 mln subordinate voting shares by selling shareholders)
  • BMY -2.3% (announces that Phase 3 CheckMate -451 Opdivo study did not meet its primary endpoint)
  • SABR -2.2% (pricing of secondary public offering of 23,304,636 shares of common stock at $24.95 per share)
  • TSLA -2.2% (October China sales fall 70%)
  • AAPL -2% (on potential iPhone tariffs)
  • LW -1.5% (to join S&P 500)
  • CMCM -1.3% (Cheetah Mobile responds to BuzzFeed article regarding attribution of app installations -- is in communication with all SDK providers to investigate the allegations)

Analyst comments:

  • MAC -1% (downgraded to Underweight at Morgan Stanley)

>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance:

  • SDRL +6.2%, AQUA +5.4%, STNE +3.2%, MTSC +2.8%, ENTA +2.2%, UNH +1%, CAAP +1%

M&A news:

  • ADS +0.5% (exploring strategic alternatives for Epsilon business)

Other news:

  • ABEO +11.9% ( announces immediate termination of CEO Dr. Carsten Thiel due to "personal misconduct"; appoints Chief Medical Officer Dr. João Siffert as Interim CEO)
  • SAVE +10.8% (sees Q4 TRASM +11% y/y and modestly improved Q4 range for CASM ex fuel)
  • MXIM +4.7% (to join S&P 500)
  • LOXO +3.4% (receives FDA approval for Vitrakvi)
  • FANG +2.9% (to join S&P 500)
  • PCG +1.5% (extending today's move higher)
  • RCKT +1.5% (FDA has granted Regenerative Medicine Advanced Therapy and Fast Track designations to RP-L102; announces public offering of $50 mln of shares of its common stock)
  • ZYME +0.8% (Zymeworks and BeiGene (BGNE) enter strategic collaboration for the clinical development and commercialization of Zymeworks' investigational ZW25 and ZW49 HER2-targeted bispecific antibodies)
  • MRK +0.7% (ticking higher on BMY Phase 3 CheckMate -451 Opdivo study results)
  • MNK +0.7% (following Citron related decline)
  • UTX +0.6% (United Tech to separate into three independent companies and updates outlook to reflect completion of its acquisition of Rockwell Collins)

>>> US Early premarket gappers

Early premarket gappers

Gapping up:

  • ABEO +11.9%, SDRL +8.5%, SAVE +6%, MXIM +4%, STNE +3.7%, MTSC +2.8%, FANG +2.5%, ENTA +2.2%, CAAP +1%, CBRL +0.9%, PCG +0.9%, ZYME +0.8%, MRK +0.7%, MNK +0.7%, UTX +0.5%

Gapping down:

  • GSM -31.9%, HALO -12.3%, FRAN -11.7%, GTHX -11.1%, BKE -7.1%, AMRN -6.8%, ACAD -6.5%, IMGN -4.9%, KOS -3.8%, SABR -2.7%, MTL -2.5%, DXCM -2.4%, BMY -2.3%, AAPL -1.8%, LW -1.5%, TSLA -1.5%, SWX -1.4%, GOOS -1.3%, MAC -0.6%, HIBB -0.6%